Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Raptor Buy Bolsters Horizon's Orphan Business As Primary Care Foots The Bill

Executive Summary

Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.

Advertisement

Related Content

Mercaptor Wants To Reinvent Drug Discovery And Development With No Pharma Or VC Funding
Biopharma Quarterly Dealmaking Statistics, Q3 2016
Post Depomed Deal Flop, Horizon Buys Crealta For $510m
Horizon Seeks Other Deals As Depomed Thwarts Takeover
Raptor Falls On Failed Investigator-Run NASH Study
Horizon Pharma signs $1.1bn deal to buy Hyperion
Horizon buying Vidara for Actimmune, Irish HQ

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097284

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel